Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 8, 2008, Pages 756-765

  Peretti, Thais ^a   Waisberg, Jaques ^b   Mader, Ana Maria A A ^d   De Matos, Leandro L ^e   Da Costa, Ricardo B ^c   Conceição, Gleice Margarete De S ^a   Lopes, Antônio Carlos ^a   Nader, Helena B ^a   Pinhal, Maria Aparecida S ^a,e  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

^c Laboratório Ferdinando Costa Patologia Cirúrgica   (Brazil)

^d Hospital Estadual Mario Covas   (Brazil)

^e FACULDADE DE MEDICINA DO ABC   (Brazil)

Author keywords

Colorectal carcinoma; Heparanase 2; Immunohistochemistry; Proteoglycans; Syndecan 1

Indexed keywords

HEPARANASE; HEPARANASE 2; SYNDECAN 1; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; SDC1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; COLORECTAL CARCINOMA; COMPUTER ANALYSIS; CONTROLLED STUDY; CYTOPLASM; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; LARGE INTESTINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STAINING; STATISTICAL ANALYSIS; TUMOR GROWTH; ADENOCARCINOMA; ADULT; AGED; ANTIBODY SPECIFICITY; CELL CULTURE; COLORECTAL TUMOR; ENZYME IMMUNOASSAY; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODY SPECIFICITY; COLORECTAL NEOPLASMS; EXTRACELLULAR MATRIX; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; SENSITIVITY AND SPECIFICITY; SYNDECAN-1; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 52749090925     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282fc2649     Document Type: Article

References (59)

1. Chen WC, Lin MS, Zhang BF, Fang J, Zhou Q, Hu Y, Gao HJ. Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray. World J Gastroenterol 2007; 13:699-708.
2. Li BH, Zhao P, Liu SZ, Yu YM, Han M, Wen JK. Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. World J Gastroenterol 2005; 11:3046-3050.
3. Xie D, Sham JS, Zeng WF, Che LH, Zhang M, Wu HX, et al. Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression. World J Gastroenterol 2005; 11:3285-3289.
4. Bernfield M, Götte M, Park PM, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Ver Biochem 1999; 68:729-777.
5. Benhamron S, Nechushtan H, Verbovetski I, Krispin A, Abboud-Jarrous G, Zcharia E, et al. Translocation of active heparanase to cell surface regulates degradation of extracellular matrix heparin sulfate upon transmigration of mature monocyte-derived dendritic cells. J Immunol 2006; 176:6417-6424.
6. Scott JE. Structure and function in extracellular matrices depend of interactions between anionic glycosaminoglycans. Pathol Biol 2001; 49:284-289.
7. Yamada KM. Adhesive recognition sequences. J Biol Chem 1991; 266:12809-12812.
8. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001; 108:349-355.
9. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001; 108:169-173.
10. Salmivirta M, Jalkanen M. Syndecan family of cell surface proteoglycans: developmentally regulared receptors for extracellular effector molecules. Experientia 1995; 51:863-872.
11. Franco CR, Rocha HA, Trindade ES, Santos IA, Leite EL, Veiga SS, et al. Heparan sulfate and control of cell division: adhesion and proliferation of mutant CHO-745 cells lacking xylosyl transferase. Braz J Med Biol Res 2001; 34:971-975.
12. Dietrich CP, Sampaio LO, Toledo OM, Cassaro CM. Cell recognition and adhesiveness: a possible biological role for the sulfated mucopolysaccharides. Biochem Biophys Res Commun 1977; 75:329-336.
13. Dietrich CP, Martins JR, Sampaio LO, Nader HB. Anomalous structure of urinary chondroitin sulfate from cancer patients. A potencial new marker for diagnosis of neoplasias. Lab Invest 1993; 68:439-445.
14. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Ver Biochem 1998; 67:609-652.
15. Lundin M, Nordling S, Lunding J, Isola J, Wiksten JP, Haglund C. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 2005; 68:306-313.
16. Day RM, Hae X, Ilyas M, Daszak P, Talhot IC, Forbes A. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch 1999; 434:121-125.
17. Mikami S, Ohashi K, Nemote T, Katsube K, Yanashigita M, Nakagima M, et al. Loss of syndecan-1 and increased expression of heparanase in invasive esophagial carcinomas. Jap J Cancer Res 2001; 92:1062-1073.
18. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD Jr, et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 2007; 4:13326-13333.
19. Reiland J, Sanderson RD, Wagnespack M, Barker SA, Long R, Carson DD, Marchetti D. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem 2004; 279:8047-8055.
20. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, et al. Heparanase influence expression and sheddin of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007; 109:4914-4923.
21. Yang Y, Macleod V, Dai Y, Khotskaya Sample Y, Shriver Z, Venkataraman G, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007; 110:2041-2048.
22. Reiland J, Kempt D, Roy M, Denkins Y, Marchetti D. FGF2 Binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia 2006; 8:596-606.
23. Baker E, Crawford J, Sutherland GR, Freeman C, Parish CR, Hulett MD. Human HPA endoglycosidase heparanase. Map position 4q21.3. Chromosome Res 1999; 7:319.
24. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V. Lymphoma cell mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res 1983; 43:2704-2711.
25. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992; 12:112-127.
26. Vlodavsky I, Goldshmidt O. Properties and function of heparanase in cancer metastasis and angiogenesis. Haemostasis 2001; 1:60-63.
27. Mackenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, et al. Cloning and expression of profiling of HPA2, a novel mammalian heparanase family member. Biochem Biophys Res Comm 2000; 276:1170-1177.
28. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 2000; 25:349-351.
29. Nadav L, Eldor A, Yacoby-Zeevi O, Zamir E, Pecker I, Ilan N, et al. Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J Cell Sci 2002; 115:2179-2187.
30. Nobuhisa T, Naomoto Y, Ohkawa T, Takaoka M, Ono R, Murata T, et al. Heparanase expression correlates with malignant potential in human colon cancer. J Cancer Res Clin Oncol 2005; 131:229-237.
31. Naomoto Y, Takaoka M, Okawa T, Nobuhisa T, Gunduz M, Tanaka N. The role of heparanase in gastrointestinal cancer (Review). Oncol Rep 2005; 14:3-8.
32. Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, Pappo O. Expression of heparanase in normal, dysplasic and neoplasic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 2000; 157:1167-1175.
33. Inki P, Jalkanen M. The role of syndecan-1 in malignancies. Ann Med 1996; 28:63-67.
34. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991; 60:443-475.
35. Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, Elkin M, et al. Mammalian heparanase involvement in cancer metastasis, angiogenesis and normal development. Cancer Biol 2002; 12:121-129.
36. Freeman C, Parish CR. Human platelet heparanase: purification, characterization and catalytic activity. Biochem J 1998; 330:1341-1350.
37. Toyoshima M, Nakajima M. Human Heparanase: purification, characterization, cloning and expression. J Biol Chem 1999; 274: 24153-24160.
38. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, et al. Mammalian heparanase: gene, cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5:793-802.
39. Matos LL, Stabenow E, Tavares MR, Ferraz AR, Capelozzi VL, Pinhal MA. Immunohistochemistry quantification by digital computer-assisted method compared to semiquantitative analysis. Clinics 2006; 61:417-424.
40. Fonseca FL, Sant Ana AV, Bendit I, Arias V, Costa LJ, Pinhal AA, del Giglio A. Systemic chemoterapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients. Breast Cancer Res 2005; 7:28-32.
41. Lopes CC, Toma L, Pinhal MA, Porcionatto MA, Sogayar MC, Dietrich CP, Nader HB. EJ-ras oncogene transfection of endothelial cells upregulates the expression of syndecan-4 and downregulates heparan sulfate sulfontransferases and epimerase. Biochimie 2006; 88:1493-1504.
42. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471:M99-M108.
43. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108:341-347.
44. Sato T, Yamaguchi A, Goi T, Hirono Y, Takeuchi K, Katayama K, Matsukawa S. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol 2004; 87:174-181.
45. Xu X, Ouiros RM, Maxhimer JB, Jiang P, Marcinek R, Ain KB, et al. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res 2003; 9:5968-5979.
46. El-Assal ON, Yamanoi A, Ono T, Cono H, Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 2001; 7:1299-305.
47. Kim AW, Xu X, Hollinger EF, Gattuso P, Godellas CV, Prinz RA. Human heparanase-1 gene expression in pancreatic adenocarcinoma. J Gastrointest Surg 2002; 6:167-172.
48. Gohji K, Hirano H, Okamoto M, Kitazawa S, Toyoshima M, Dong J, et al. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer 2001; 95:295-301.
49. Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol 2003; 14:1505-1510.
50. Maxhimer JB, Quiros RM, Stewart R, Dowlatshahi K, Gattuso P, Fan M, et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 2002; 132:326-333.
51. Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, Uno F, et al. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 2003; 83:613-622.
52. Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, et al. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 2005; 11:1028-1036.
53. Beckhove P, Helmke BM, Ziouta Y, Bucur M, Dorner W, Mogler C, et al. Heparanase expression at the invasion front of human head and neck cancers and correlation with poor prognosis. Clin Cancer Res 2005; 11:2899-2906.
54. Doviner V, Maly B, Kaplan V, Gingis-Velitski S, Ilan N, Vlodavsky I, Sherman Y. Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol 2006; 19: 878-888.
55. Zetser A, Levy-Adam F, Kaplan V, Gingis Velitski S, Bashenko Y, Schubert S, et al. Processing and activation of latent heparanase in lysosomes. J Cell Sci 2004; 117:2249-2258.
56. Zetser A, Bashenko Y, Miao H-Q, Vlodavsky I, Ilan N. Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 2003; 63:7733-7741.
57. Goldshmidt O, Zcharia E, Cohen M, Aingorn H, Cohen I, Nadav L, et al. Heparanase mediates cell adhesion independent of enzymatic activity. FASEB J 2003; 17:1015-1025.
58. Sotnikov I, Herhkoviz R, Grabovsky V, Ilan N, Cahalon L, Vlodavsky I, et al. Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol 2004; 172:5185-5193.
59. Theodoro TR, de Matos LL, Sant Anna AVL, Fonseca FLA, Semedo P, Martins LC, et al. Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. Neoplasia 2007; 5:504-510.